Insilico Medicine's multimodal foundation model, Nach01, accelerates drug discovery by integrating molecule generation, property prediction, and downstream analysis within a secure Azure environment. This integration enables unified, AI-native workflows for computational drug discovery.
Researchers use AI-driven target discovery platform to identify PRPF19 and MAPK9 as promising targets that suppress tumor cell proliferation while reducing senescence-associated signaling. The study suggests these dual-purpose targets may address both hepatocellular carcinoma progression and cellular senescence.
Insilico Medicine's Phase IIa clinical trial assesses Garutadustat's safety and efficacy in ulcerative colitis. The novel PHD inhibitor has shown favorable safety and tolerability profiles in completed Phase I studies.
Leadership from Insilico Medicine will discuss its groundbreaking collaboration with Capgemini, showcasing Pharmaceutical Superintelligence in action. The company's diversified pipeline includes 40+ programs discovered using Pharma.AI, with positive topline results from a Phase IIa trial for idiopathic pulmonary fibrosis.
DORA Community Edition aims to democratize access to state-of-the-art research tools, foster global collaboration, and accelerate innovation in biotechnology. The open-source version is designed to streamline the drafting of academic papers and other research-related documents with a team of agile AI agents.
Insilico Medicine collaborates with Servier to develop novel therapeutics in oncology through AI-driven platform Pharma.AI. The partnership is focused on identifying promising targets and generating molecular structures with desired properties.
Insilico Medicine and Hisun Pharma successfully nominated a preclinical candidate using AI-powered R&D in just 8 months after forming a strategic collaboration. The collaboration showcased the acceleration and efficiency gains that AI can bring to drug development, enabling the companies to enhance innovation in early-stage drug discov...
Insilico Medicine raised a total of HKD 2.277 billion in its largest Hong Kong biotech IPO, with 94,690,500 shares offered globally and oversubscribed by approximately 1427 times. The company aims to advance its mission of extending human productive longevity using AI-powered drug discovery and development.
Insilico Medicine showcases its Pharma.AI platform's capabilities in generating biologics and analyzing data to accelerate drug discovery. The company's latest updates include improved Generative Biologics, Chemistry42/Nach01, and PandaOmics features.
Insilico Medicine and Taigen Biotechnology collaborate to develop and commercialize ISM4808, an AI-driven PHD inhibitor for treating anemia of Chronic Kidney Disease (CKD). The partnership grants TaiGen exclusive rights for further development, commercialization, and sub-licensing in the Greater China area.
Insilico Medicine's AI platforms enable discovery of a novel, potent, selective, and orally administered DGKα inhibitor that restores T cell function and overcomes checkpoint resistance. The compound exhibits strong combination activity with anti–PD-1 and anti–CTLA-4 therapies in preclinical studies.
Insilico Medicine's Chemistry42 platform enables the efficient discovery of a potent, oral CBLB inhibitor with low toxicity risks and favorable ADME/PK profiles. The compound demonstrates strong in vitro activity and improved metabolic stability in mouse, rat, and dog models.
The latest Pharma.AI updates focus on generating precision in binder design and analyzing patent information. Insilico's AI-powered platform now boosts biological intelligence by up to 10 times, accelerating drug discovery processes.
Researchers used Insilico's AI-powered PandaOmics platform to identify (Z)-endoxifen as a promising therapeutic candidate for glioblastoma, with strong reversal of biological programs driving tumor growth and treatment resistance. Laboratory validation confirmed the compound's cytotoxic activity and showed enhanced effects in combination.
Researchers at Insilico Medicine developed an AI-empowered dual-action PROTAC targeting PKMYT1, which induces degradation and inhibits kinase activity. The lead compound, D16-M1P2, exhibits high selectivity, potent anti-tumor activity, and favorable oral bioavailability.
Insilico Medicine will demonstrate how generative AI is accelerating therapeutic discovery, improving drug efficacy, and advancing personalized medicine. The company's pharma superintelligence platform aims to tackle challenging problems in modern science and medicine.
Insilico Medicine has nominated ISM3830, a highly selective CBLB inhibitor, as a preclinical candidate for advanced tumor immunotherapy. ISM3830 showed robust anti-tumor activity in multiple murine models and induction of long-term tumor immunity.
Dr. Zhavoronkov's exceptional research influence has been validated by Clarivate, with over 310 peer-reviewed papers since 2012. His work has garnered over 16,500 citations per Google Scholar, primarily on generative adversarial networks and reinforcement learning for drug discovery.
Insilico Medicine is set to showcase its latest AI-driven Pulmonary Fibrosis clinical research at the PFF Summit 2025 in Chicago, IL. The company's Rentosertib (INS018_055/ISM001-055), a novel AI-designed TNIK inhibitor, has demonstrated promising therapeutic outcomes and potential markers of patient response.
The collaboration combines Insilico's Pharma.AI platforms with Lilly's expertise to discover and advance new therapies. Insilico will utilize its platform to generate candidate compounds, accelerating the development of transformative treatments for urgent patient needs.
Insilico Medicine launches innovative cardiometabolic disease portfolio powered by its proprietary Pharma.AI platform, targeting established and moderate-novelty targets. The portfolio features two novel GLP-1RAs designed for improved safety and pharmacokinetics at low dose to allow multi-pill combinations.
Insilico Medicine has demonstrated the potential of generative biologics to rapidly design peptides targeting GLP1R, a receptor modulated by blockbuster diabetes drugs. The company generated over 5,000 novel peptides within a 72-hour cycle and identified 14 with biological activity.
Insilico Medicine has been named a 2025 BostInno Fire Awards honoree for its groundbreaking achievements in AI-driven drug discovery. The company's lead asset, Rentosertib (ISM001-055), demonstrated potential signs of lung function restoration in idiopathic pulmonary fibrosis patients.
Insilico Medicine will introduce its emerging Cardiometabolic Portfolio and showcase the capabilities of its end-to-end Pharma.AI platform at BIO-Europe 2025. The company's business development team will be available for meetings to pursue strategic collaborations.
Insilico Medicine's Alex Zhavoronkov and Alex Aliper will share their insights on generative AI breakthroughs in healthcare. The company is leveraging AI to accelerate drug discovery, reducing the time from traditional methods by 2.5-4 years.
At the 2025 Fortune Global Forum, Insilico Medicine's CEO Dr. Alex Zhavoronkov will share his vision for a future where generative AI can help humanity live better and longer. The company has advanced its AI algorithm development and built industry collaborations across the Middle East.
Insilico Medicine has released several AI-powered tools, including PandaOmics and Generative Biologics, to accelerate drug discovery. These platforms utilize machine learning and AI models to analyze large datasets and generate novel hypotheses.
Pharma.AI is a comprehensive generative AI-powered drug discovery platform featuring PandaOmics, Generative Biologics, Chemistry42, Science42: DORA, and PreciousGPT. These platforms enhance target and biomarker discovery, biologics engineering, small molecule design, scientific research, and disease modelling.
Insilico Medicine's founder Alex Zhavoronkov, PhD, is named among 100 global leaders driving the future of artificial intelligence. The company has developed breakthrough solutions for novel target discovery and drug development using generative AI.
The partnership enables AI-driven design, antibody development, payload-linker synthesis, and clinical development to accelerate ADC drug discovery and development. The collaboration aims to deliver more effective treatment options for cancer patients worldwide by integrating cutting-edge technology and expertise.
The global market for AI in pharmaceuticals is projected to reach $13.4 billion by 2035, driven by Insilico Medicine's innovative use of generative AI. The company will share its achievements at a satellite forum during BIOHK2025, showcasing significant efficiency boosts compared to traditional methods.
The ARDD conference will unveil the latest advancements in cell simulation, deep aging biomarkers, and cellular aging mechanisms, driving healthy longevity research forward. Insilico Medicine is a pioneer in this field with AI-driven research on aging and longevity.
Insilico Medicine has completed IND-enabling studies for ISM8969, an orally available NLRP3 inhibitor targeting inflammation and neurodegenerative disorders. The drug candidate demonstrated favorable PD/PK profiles and dose-dependent efficacy in motor functions in animal models.
Researchers at Insilico Medicine used AI tools to investigate the connection between IPF and accelerated aging, identifying four key pathways central to both conditions. The study found that patients with severe infections had significantly higher predicted biological ages, suggesting a link between fibrosis and aging.
The Insilico Medicine recent summer updates webinar introduced new features and functional updates to the company's generative AI platform, including Generative Biologics, Chemistry42, PandaOmics, DORA, and PreciousGPT. These updates aim to accelerate drug discovery and advance life sciences research.
Insilico Medicine's latest Pharma.ai updates showcase advancements in Biology42 and Chemistry42, enhancing antibody design and omics data analysis. The company's AI software suite has demonstrated significant efficiency improvements in practical applications, setting a benchmark for AI-driven drug research.
At the upcoming AI for Good Global Summit, Alex Zhavoronkov PhD will discuss the future potential of generative AI. Insilico Medicine's founder and CEO has invented critical technologies in generative AI and reinforcement learning, and his keynote will explore applications in drug discovery and longevity.
Researchers employed advanced molecular modeling and generative AI to design highly selective FGFR2/3 inhibitors, overcoming therapeutic resistance in various cancers. ISM7594 exhibited nanomolar inhibitory activity against FGFR2/3 with over 100-fold selectivity, showing robust antiproliferative effects.
Insilico Medicine secured a position among the Top 100 global corporate institutions for biological sciences and natural sciences publications. The company's remarkable rise was driven by two studies published in Nature Biotechnology, highlighting the transformative potential of AI in providing solutions for unmet medical needs.
The collaboration aims to bridge academia and industry through joint research projects, academic exchange, and hands-on training for students and faculty. The partnership also opens career opportunities for UAEU graduates at Insilico, fostering local talent and supporting the expansion of the UAE's biotechnology sector.
Insilico Medicine has completed the first-in-patient dosing of ISM3412, a novel MAT2A inhibitor with potential as a best-in-class treatment for locally advanced and metastatic solid tumors. The Phase 1 study aims to evaluate safety, tolerability, and preliminary anti-tumor efficacy of ISM3412.
Nach01, a large language model-based foundation model, leverages structural and spatial data for diverse chemical tasks. The model is now available on AWS Marketplace, streamlining access for researchers and pharma companies to build and apply large-scale generative models.
The Phase IIa trial of Rentosertib showed encouraging clinical data, with patients receiving the treatment experiencing significant improvements in lung function compared to placebo. The study also validated the biological mechanism of TNIK inhibition using exploratory biomarkers analyses.
Researchers developed novel ENPP1 inhibitors to modulate the STING pathway and enhance tumor immunity, overcoming challenges faced by direct STING agonists. The top candidate compound ISM5939 demonstrates high selectivity and potency for ENPP1 inhibition, potentiating effects of existing cancer treatments.
Researchers discovered novel small-molecule inhibitors targeting the WDR5-MYC protein-protein interaction, demonstrating improved inhibitory activity compared to reference compounds. The lead compound, 9c-1, showed a 35-fold enhancement in activity and sub-micromolar binding affinity.
Insilico Medicine is launching a pilot project in the UAE to discover a novel drug candidate for oncology therapeutics using its proprietary Pharma.AI platform. The project aims to accelerate traditional drug discovery timelines and leverage local talent to create world-class therapeutics.
Insilico Medicine will present detailed Phase IIa data on rentosertib, a novel TNIK inhibitor developed using generative AI, for the treatment of idiopathic pulmonary fibrosis (IPF). The company has previously demonstrated encouraging results from its Phase IIa study, showing favorable safety and tolerability across all dose levels.
Insilico Medicine's Pharma.AI Day 2025 will showcase the latest AI breakthroughs and updates, including precision target discovery engine PandaOmics and generative biologics platform Generative Biologics. The company aims to accelerate drug discovery and advance life sciences research with its proprietary platform.
Insilico Medicine is presenting significant achievements in cancer therapy and immunology, including AI-powered discovery of potential therapies and novel solutions for unmet needs. The company's Pharma.AI platform has received IND clearance for 10 molecules, with promising results in Phase 2a clinical studies.
Insilico Medicine is a pioneer in generative AI-driven healthcare, showcasing its Pharma.AI platform and pipeline portfolio featuring IND clearance molecules. The company will share insights at Abu Dhabi Global Health Week panel discussions, focusing on longevity and precision health.